3796 Fumitremorgin A Fumitremorgin A (FTA) is a potent neurotropic and tremorgenic mycotoxin isolated from Aspergillus fumigatus. Tremorgenic mycotoxins affect the central nervous system causing sustained tremors, convulsions, and death and have been implicated in a number of neurologic diseases of cattle collectively known as "staggers syndromes". FTA also severely affects the autonomic nervous system, likely through abnormal excitation of the central nervous system. (A2976, A3024) 12626-18-5 107713 C32H41N3O7 White powder. Oral, dermal, inhalation, and parenteral (contaminated drugs). (A3101) Tremorgenic mycotoxins exert their toxic effects by interfering with neurotransmitter release, possibly by causing degeneration of nerve terminals. They are thought to inhibit gamma-aminobutyric acid (GABA) receptors, both pre- and postsynaptic, as well as inhibit transmitter breakdown at the GABA-T receptors. This would initially increase neurotransmitter levels, potentiating the GABA-induced chloride current, then lead to decreased levels of neurotransmitter in the synapse. (A2974, A2975, A2976) No indication of carcinogenicity to humans (not listed by IARC). Fumitremorgin A (FTA) is mycotoxin isolated from Aspergillus fumigatus. (A3024) Tremorgenic mycotoxins affect central nervous system activity. They cause a neurological disease of cattle known as "staggers syndrome". (A2976) Tremorgenic mycotoxins affect central nervous system activity, inducing neurologic symptoms including mental confusion, paralysis, tremors, seizures, and death. They cause a neurological disease of cattle known as "staggers syndrome", which is characterized by muscle tremors and hyperexcitability. Fumitremorgin A exposure has also been shown to cause bradycardia, arrhythmia, and hypertension. (A2974, A3025) To control severe tremors caused by tremorgenic mycotoxins, methocarbamol should be administered. Generalized seizures may be treated with diazepam followed by methocarbamol or a barbiturate such as pentobarbital sodium. Gastric lavage should be performed and activated charcoal administered to limit further absorption of toxins. (A744) 2010-05-10T14:30:53Z 2026-04-06T10:14:48Z true COC1=CC2=C(C=C1)C1=C3C(CC(C)(C)OOC(C=C(C)C)N23)N2C(=O)C3CCCN3C(=O)C2(O)C1OCC=C(C)C C32H41N3O7 InChI=1S/C32H41N3O7/c1-18(2)12-14-40-28-26-21-11-10-20(39-7)16-23(21)34-25(15-19(3)4)41-42-31(5,6)17-24(27(26)34)35-29(36)22-9-8-13-33(22)30(37)32(28,35)38/h10-12,15-16,22,24-25,28,38H,8-9,13-14,17H2,1-7H3 ACGHJVZDNQZJOV-UHFFFAOYSA-N 579.6838 579.294450681 Exogenous Solid CHEM002710 NS00120020 23-hydroxy-5-methoxy-12,12-dimethyl-24-[(3-methylbut-2-en-1-yl)oxy]-9-(2-methylprop-1-en-1-yl)-10,11-dioxa-8,15,21-triazahexacyclo[12.10.1.0²,⁷.0⁸,²⁵.0¹⁵,²³.0¹⁷,²¹]pentacosa-1(25),2(7),3,5-tetraene-16,22-dione